Logo image of AGRX

AGILE THERAPEUTICS INC (AGRX) Stock Fundamental Analysis

NASDAQ:AGRX - Nasdaq - US00847L3087 - Common Stock - Currency: USD

0.6022  +0.06 (+10.11%)

After market: 0.2408 -0.36 (-60.01%)

Fundamental Rating

2

Overall AGRX gets a fundamental rating of 2 out of 10. We evaluated AGRX against 198 industry peers in the Pharmaceuticals industry. AGRX may be in some trouble as it scores bad on both profitability and health. AGRX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AGRX had negative earnings in the past year.
AGRX had a negative operating cash flow in the past year.
In the past 5 years AGRX always reported negative net income.
AGRX had a negative operating cash flow in each of the past 5 years.
AGRX Yearly Net Income VS EBIT VS OCF VS FCFAGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

AGRX's Return On Assets of 75.60% is amongst the best of the industry. AGRX outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 75.6%
ROE N/A
ROIC N/A
ROA(3y)-143.37%
ROA(5y)-111.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGRX Yearly ROA, ROE, ROICAGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

1.3 Margins

AGRX has a better Profit Margin (41.26%) than 97.00% of its industry peers.
Looking at the Gross Margin, with a value of 57.79%, AGRX is in the better half of the industry, outperforming 66.00% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 41.26%
GM 57.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGRX Yearly Profit, Operating, Gross MarginsAGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

More info and screens

0

2. Health

2.1 Basic Checks

AGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for AGRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AGRX Yearly Shares OutstandingAGRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 200K 400K 600K 800K
AGRX Yearly Total Debt VS Total AssetsAGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -59.60, we must say that AGRX is in the distress zone and has some risk of bankruptcy.
AGRX has a worse Altman-Z score (-59.60) than 92.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.6
ROIC/WACCN/A
WACC10.87%
AGRX Yearly LT Debt VS Equity VS FCFAGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M -60M

2.3 Liquidity

AGRX has a Current Ratio of 0.58. This is a bad value and indicates that AGRX is not financially healthy enough and could expect problems in meeting its short term obligations.
AGRX's Current ratio of 0.58 is on the low side compared to the rest of the industry. AGRX is outperformed by 93.00% of its industry peers.
A Quick Ratio of 0.44 indicates that AGRX may have some problems paying its short term obligations.
AGRX has a Quick ratio of 0.44. This is amonst the worse of the industry: AGRX underperforms 93.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.44
AGRX Yearly Current Assets VS Current LiabilitesAGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

AGRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.64%, which is quite impressive.
The Revenue has grown by 137.74% in the past year. This is a very strong growth!
EPS 1Y (TTM)97.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.98%
Revenue 1Y (TTM)137.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%122%

3.2 Future

Based on estimates for the next years, AGRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.10% on average per year.
The Revenue is expected to grow by 61.60% on average over the next years. This is a very strong growth
EPS Next Y93.92%
EPS Next 2Y41.61%
EPS Next 3Y26.27%
EPS Next 5Y15.1%
Revenue Next Year101%
Revenue Next 2Y92.19%
Revenue Next 3Y72.2%
Revenue Next 5Y61.6%

3.3 Evolution

AGRX Yearly Revenue VS EstimatesAGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
AGRX Yearly EPS VS EstimatesAGRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -500 -1K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

AGRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 0.89, the valuation of AGRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, AGRX is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.65, AGRX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.89
AGRX Price Earnings VS Forward Price EarningsAGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGRX Per share dataAGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AGRX's earnings are expected to grow with 26.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.61%
EPS Next 3Y26.27%

More info and screens

0

5. Dividend

5.1 Amount

AGRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGILE THERAPEUTICS INC

NASDAQ:AGRX (3/25/2024, 8:08:50 PM)

After market: 0.2408 -0.36 (-60.01%)

0.6022

+0.06 (+10.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-28 2024-03-28/bmo
Earnings (Next)05-09 2024-05-09/bmo
Inst Owners0.07%
Inst Owner Change0%
Ins Owners105.84%
Ins Owner Change0%
Market Cap1.51M
Analysts82.86
Price Target5.1 (746.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.75%
Min EPS beat(2)69.89%
Max EPS beat(2)85.61%
EPS beat(4)4
Avg EPS beat(4)58.91%
Min EPS beat(4)22.75%
Max EPS beat(4)85.61%
EPS beat(8)6
Avg EPS beat(8)29.72%
EPS beat(12)10
Avg EPS beat(12)23.02%
EPS beat(16)12
Avg EPS beat(16)15.68%
Revenue beat(2)1
Avg Revenue beat(2)14.37%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)32.28%
Revenue beat(4)3
Avg Revenue beat(4)16.45%
Min Revenue beat(4)-3.53%
Max Revenue beat(4)32.28%
Revenue beat(8)6
Avg Revenue beat(8)14.15%
Revenue beat(12)7
Avg Revenue beat(12)1.76%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-70.37%
EPS NQ rev (3m)-70.37%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-55.77%
Revenue NQ rev (3m)-55.77%
Revenue NY rev (1m)-20.71%
Revenue NY rev (3m)-20.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.89
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.33
EYN/A
EPS(NY)0.67
Fwd EY111.79%
FCF(TTM)-4.51
FCFYN/A
OCF(TTM)-4.51
OCFYN/A
SpS7.96
BVpS-4.94
TBVpS-4.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 75.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 41.26%
GM 57.79%
FCFM N/A
ROA(3y)-143.37%
ROA(5y)-111.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.44
Altman-Z -59.6
F-Score5
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)48.55%
Cap/Depr(5y)361.63%
Cap/Sales(3y)18.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.98%
EPS Next Y93.92%
EPS Next 2Y41.61%
EPS Next 3Y26.27%
EPS Next 5Y15.1%
Revenue 1Y (TTM)137.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%122%
Revenue Next Year101%
Revenue Next 2Y92.19%
Revenue Next 3Y72.2%
Revenue Next 5Y61.6%
EBIT growth 1Y60.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.84%
OCF growth 3YN/A
OCF growth 5YN/A